The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | SWIFT-Seq: single-cell RNA sequencing of CTCs for patients with multiple myeloma and precursors
Elizabeth D. Lightbody, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses SWIFT-Seq, a novel method utilizing single-cell RNA sequencing of circulating tumor cells (CTCs) in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and newly diagnosed multiple myeloma (NDMM). The technique enables the profiling of limited CTCs in blood, assessing their proliferation rate, cytogenetic profile, and gene expression profile. This innovative approach consolidates multiple assays into a single test, reducing costs and improving clinical and biological insights. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
